% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • dvnmonk dvnmonk Mar 5, 2014 8:27 PM Flag

    5 Insider Sec Form 4 Filings 3/4/2014 - Purchased at $6.15

    No lack of confidence from insiders - found 5 Insider Sec Form 4 Filings 3/4/2014 - purchased at $6.15 Go to company website under SEC filings to view...

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "The original post is referring to transactions that took place today - see investors/sec filings. All but those of Friedman were grants"

      Excellent find ! So Friedman BOUGHT as of 2 days ago. The only missing piece is WHO will be the next CEO. With earning report coming in few days, the CEO announcement can not be this far off.

      Sentiment: Strong Buy

    • Gentlemen.

      Great find of the new insiders buy !

      Has to comments made that insider used options: You are WRONG ! SNTA insiders bought in PUBLIC offering ! NOT options grants.

      One more nugget : 0 (ZERO) shares SOLD by insiders. ZERO !

      Here is an article on the issue with more info:

      Insiders Are Buying Synta Pharmaceuticals

      Nov. 18, 2013 5:26 AM ET | 9 comments | About: SNTA, Includes: CRIS, EXEL, INFI
      Disclosure: I am long EXEL. (More...)
      In this article, I will feature one biotech stock that has seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:

      The stock is purchased by three or more insiders within one month.
      The stock is sold by no insiders in the month of intensive purchasing.
      At least two purchasers increased their holdings by more than 10%.
      Synta Pharmaceuticals (SNTA) focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases.

      (click to enlarge)

      Insider buying during the last 30 days

      Here is a table of Synta's insider-trading activity during the last 30 days by insider.

      Name Title Trade Date Shares Purchased Public Offering Current Ownership Increase In Shares
      Safi Bahcall CEO Nov 13 20,000 Yes 2,053,135 shares +1.0%
      William Reardon Director Nov 13 13,333 Yes 36,561 shares +57.4%
      Keith Gollust Director Nov 13 150,000 Yes 3,330,638 shares +4.7%
      Bruce Kovner Director Nov 13 5,000,000 Yes 28,641,849 shares +21.1%
      There have been 5,183,333 shares purchased by insiders during the last 30 days.

      Insider buying by calendar month

      Here is a table of Synta's insider-trading activity by calendar month.

      Month Insider buying / shares Insider selling / shares
      November 2013 5,183,333 0
      October 2013 0 0
      September 2013 0 0
      August 2013 0 0
      July 2013 0 0
      June 2013 3,170,000 0
      May 2013 0 0
      April 2013 0 0
      March 2013 0 0
      February 2013 0 0
      January 2013 0 0


      Sentiment: Strong Buy

    • Never a dull moment! The one I checked got 115,000. Maybe that's why they canned Safi when they did - so they didn't have to grant him any options. Seems like something's up.

      • 1 Reply to factspls88
      • Cont:
        There have been 8,353,333 shares purchased and there have been zero shares sold by insiders this year. The month of November has seen the most insider buying.


        Synta reported the third-quarter financial results on November 4 with the following highlights:

        Revenue $0
        Net loss $22.5 million
        Cash $53.4 million
        Debt $23.5 million
        On November 13, 2013, Synta priced a public offering of 14,000,000 shares of its common stock at a price to the public of $3.75 per share. Gross proceeds to Synta are expected to be approximately $52.5 million.

        Pipeline and upcoming catalysts

        Synta has the following upcoming catalysts:

        Trial Catalyst
        GALAXY-1 Overall survival results by early 2014.
        GALAXY-2 Interim analyses in H2/2014, final analysis in H1/2015.
        ENCHANT-1 Initial results in December 2013.
        (click to enlarge)

        (Source: Synta)


        Synta's competitors include Infinity Pharmaceuticals (INFI), Curis (CRIS), and Exelixis (EXEL). Here is a table comparing these companies.

        Company SNTA INFI CRIS EXEL
        Market Cap: 292.06M 689.98M 237.16M 974.44M
        Employees: 124 154 33 174
        Revenue: N/A N/A 15.16M 34.81M
        EBITDA: -74.05M -138.80M -8.18M -170.83M
        Net Income: -76.63M -140.84M -20.50M -226.21M
        P/S: N/A N/A 15.92 28.26
        Synta doesn't have any revenues yet.

        Here is a table of these competitors' insider-trading activities this year.

        Company Insider buying / shares Insider selling / shares
        INFI 0 5,781,169
        CRIS 90,000 481,852
        EXEL 10,000 0
        Only Synta has seen intensive insider buying during the last 30 days


        There have been four different insiders buying Synta and there have not been any insiders selling Synta during the last 30 days. Two of these four insiders increased their holdings by more than 10%.

        On October 26, 2013, Synta announced one-year follow-up results from the GALAXY-1 Phase 2b/3 trial. The stock plunged after the results due to improved performance by the control arm.

        The insiders purchased their shares after the GALAXY-1 trial CONT.

        Sentiment: Strong Buy

    • Stock options granted. No skin in the game. Hate when companies recklessly issue them. Wish it was good news, but means nothing.

    • They (insiders) were granted stock options. They did not purchase any stock.

    • Excellent post! Our PPS is more than likely to rebound on this Insider activity. Dont over analyze the situation here!!!

0.343+0.072(+26.61%)Jul 22 4:00 PMEDT